Protara Therapeutics Announces Addition to the Russell 3000® Index
Protara Therapeutics (Nasdaq: TARA), a clinical-stage company focused on cancer and rare disease treatments, has been added to the Russell 3000® Index effective June 30, 2025. The company's pipeline includes clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations, as well as an IV Choline Chloride program for patients on parenteral support.
The Russell 3000® Index, which captures the 4,000 largest U.S. stocks by market capitalization, is widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes as of June 2024.
Protara Therapeutics (Nasdaq: TARA), un'azienda in fase clinica specializzata in trattamenti per il cancro e malattie rare, è stata inclusa nell'Indice Russell 3000® a partire dal 30 giugno 2025. Il portafoglio prodotti dell'azienda comprende studi clinici per TARA-002 nel carcinoma vescicale non muscolo-invasivo e malformazioni linfatiche, oltre a un programma di Cloruro di Colina endovenoso per pazienti in supporto parenterale.
L'Indice Russell 3000®, che raccoglie le 4.000 maggiori azioni statunitensi per capitalizzazione di mercato, è ampiamente utilizzato da gestori di investimenti e investitori istituzionali, con circa 10,6 trilioni di dollari in asset confrontati con gli indici Russell US a giugno 2024.
Protara Therapeutics (Nasdaq: TARA), una empresa en etapa clínica enfocada en tratamientos para el cáncer y enfermedades raras, ha sido añadida al Índice Russell 3000® con efecto a partir del 30 de junio de 2025. La cartera de la compañía incluye ensayos clínicos para TARA-002 en cáncer de vejiga no músculo invasivo y malformaciones linfáticas, así como un programa de Cloruro de Colina intravenoso para pacientes con soporte parenteral.
El Índice Russell 3000®, que agrupa las 4,000 acciones estadounidenses más grandes por capitalización de mercado, es ampliamente utilizado por gestores de inversiones e inversores institucionales, con aproximadamente 10.6 billones de dólares en activos referenciados según los índices Russell US a junio de 2024.
Protara Therapeutics (나스닥: TARA)는 암 및 희귀 질환 치료에 중점을 둔 임상 단계 기업으로, 2025년 6월 30일부터 러셀 3000® 지수에 포함되었습니다. 회사의 파이프라인에는 비근육 침습성 방광암과 림프 기형에 대한 TARA-002 임상 시험과 정맥 주사용 콜린 클로라이드 프로그램이 포함되어 있습니다.
러셀 3000® 지수는 시가총액 기준 미국 내 최대 4,000개 주식을 포함하며, 투자 관리자와 기관 투자자들이 널리 사용하고 있으며, 2024년 6월 기준 약 10.6조 달러 규모의 자산이 러셀 미국 지수를 벤치마크로 활용하고 있습니다.
Protara Therapeutics (Nasdaq : TARA), une société en phase clinique spécialisée dans les traitements du cancer et des maladies rares, a été ajoutée à l'indice Russell 3000® à compter du 30 juin 2025. Le portefeuille de la société comprend des essais cliniques pour TARA-002 dans le cancer de la vessie non invasif musculaire et les malformations lymphatiques, ainsi qu'un programme intraveineux de chlorure de choline pour les patients sous alimentation parentérale.
L'indice Russell 3000®, qui regroupe les 4 000 plus grandes actions américaines par capitalisation boursière, est largement utilisé par les gestionnaires d'investissements et les investisseurs institutionnels, avec environ 10,6 billions de dollars d'actifs référencés par rapport aux indices Russell US en juin 2024.
Protara Therapeutics (Nasdaq: TARA), ein klinisch fortgeschrittenes Unternehmen, das sich auf Krebs- und seltene Krankheitsbehandlungen spezialisiert hat, wurde zum 30. Juni 2025 in den Russell 3000® Index aufgenommen. Die Pipeline des Unternehmens umfasst klinische Studien für TARA-002 bei nicht muskelinvasivem Blasenkrebs und lymphatischen Fehlbildungen sowie ein intravenöses Cholinchlorid-Programm für Patienten mit parenteraler Unterstützung.
Der Russell 3000® Index, der die 4.000 größten US-Aktien nach Marktkapitalisierung abbildet, wird von Investmentmanagern und institutionellen Anlegern weit verbreitet genutzt und umfasst etwa 10,6 Billionen US-Dollar an Vermögenswerten, die im Juni 2024 gegen Russell US-Indizes benchmarked wurden.
- Addition to the Russell 3000® Index increases visibility among institutional investors
- Active advancement of multiple clinical trials in cancer and rare diseases
- None.
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that the Company has been added as a member of the broad-market Russell 3000® Index as part of the annual reconstitution, effective at the open of U.S. equity markets today, June 30, 2025.
“Protara’s inclusion in the Russell 3000® Index is a reflection of the progress that we have made executing across our pipeline, including the advancement of clinical trials for TARA-002 in non-muscle invasive bladder cancer and lymphatic malformations and the development of our IV Choline Chloride program for patients on parenteral support,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We are pleased to join this prestigious index to enhance the Company’s visibility amongst the financial community as we work to bring transformative therapies to patients and generate value for our stockholders."
The annual Russell US Indexes reconstitution captures the 4,000 largest US. stocks as of Tuesday, April 30, 2025 ranking them by market capitalization. Russell indices are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara’s business strategy, including its development plans for its product candidates and plans regarding the timing or outcome of existing or future clinical trials (including reporting data from approximately 25 6-month evaluable BCG-Unresponsive patients by the end of 2025); statements related to expectations regarding interactions with the U.S. Food and Drug Administration (FDA); Protara’s financial position; statements regarding the anticipated safety or efficacy of Protara’s product candidates; and Protara’s outlook for the remainder of the year and future periods. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara’s financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; failure to attract and retain management and key personnel; the impact of general U.S. and foreign, economic, industry, market, regulatory, political or public health conditions; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption “Risk Factors” and elsewhere in Protara's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
When was Protara Therapeutics (TARA) added to the Russell 3000 Index?
What are the main clinical programs in Protara Therapeutics' (TARA) pipeline?
How many assets are benchmarked against Russell US Indexes?
What type of company is Protara Therapeutics (TARA)?
